Fabrice Andre shared a post on X:

“One key mission of ESMO is to deliver Frameworks that shape the oncology practice: mcbs, escat, etac-s etc .

In this paper, a high ESMO-Magnitude of Clinical Benefit Scale was associated with faster HTA decisions.

Use of the ESMO-Magnitude of Clinical Benefit Scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis

Authors: Panos Kanavos, Erica Visintin, Aris Angelis.”

Use of the ESMO-Magnitude of Clinical Benefit Scale for HTA Recommendations

Fabrice André is a prominent medical oncologist specializing in breast cancer. He holds the position of Director of the Research Division at Gustave Roussy Cancer Center and Professor of Medicine at the University Paris Saclay. Professor André also chairs the biomarker group at UNICANCER (the French cooperative group). He is the President-Elect of the European Society for Medical Oncology (ESMO).